Sponsored

When medically complex patients transfer to LTACHs, they receive specialized ICU-level care and rehabilitation that improves outcomes and reduces readmissions.

This article was sponsored by Sanofi.

Neil Minkoff; Natasha Mesinkovska, MD; and Brett King, MD, PhD discuss the diagnosis and disease assessment in alopecia areata along with clinical considerations.

Key opinion leaders provide their final thoughts on the current disease state of endometriosis, as well as opportunities forthcoming for treatment management.

The panel shares recommendations for standardization of early education regarding endometriosis.

Dr Lopes requests panelists to share opportunities for improving disease state awareness for endometriosis.

Key opinion leaders discuss barriers regarding endometriosis, as well as opportunities to alleviate these challenges to optimize patient care.

The panel explores common disparities in the medical community impacting care for patients with endometriosis.

Expert panelists navigate patient needs and describe how to achieve successful endometriosis management from a patient perspective.

Dr Lopes leads a discussion surrounding payer considerations with an emphasis on patient-centered care in endometriosis management.

Amber Hagen, NP; Eric Surrey, MD; and Tara Hilton navigate various treatment pathways for endometriosis, including medical and surgical interventions.

Dr Surrey provides perspective regarding guideline-directed treatment options for endometriosis.

Amber Hagen, NP, and Tara Hilton provide insights on the diverse landscape and variability for treatment of endometriosis.

First-line therapies for endometriosis are explored, including drug treatment and surgical options.

A panel of experts illustrate risk factors contributing to endometriosis, as well as associated burdens affecting patients.

Maria Lopes, MD, MS, leads a panel of experts in a discussion surrounding clinical and patient burden associated with endometriosis.

A moderated digital open forum facilitating an interactive discussion among health care professionals, health system executives, health care payers, and health policy influencers about promise and the barriers to the expanded use of biosimilars in ophthalmic applications.